GlaxoSmithKline’s (GSK) triple ... a triple therapy for COPD, and could help patients manage their condition better. Around a quarter of patients use three drugs in separate inhalers and ...

GlaxoSmithKline is set to launch its COPD ... triple therapy for COPD, and could help patients manage their condition better - around a quarter of whom currently use three drugs in separate inhalers.

There was a notable gap in effectiveness between metered-dose and dry-powder formulations of single-inhaler triple therapy ...

A further 500 were given the triple combination but in two inhalers. COPD is term used to describe a number of progressive ... “This is the first long-term study to look at the possibilities of triple ...